Inventurus Knowledge Solutions expands hospital platform as TruBridge supports AI-led growth

Investment View and 1Q FY27 Performance

Motilal Oswal Financial Services retained its Buy rating on Inventurus Knowledge Solutions (IKS) after 1Q FY27 revenue broadly met expectations, while EBITDA margin and profit after tax (PAT) were below estimates. The broker views rising healthcare cost pressure in the US as a structural tailwind for IKS, whose strategy is evolving from healthcare outsourcing into an AI-enabled healthcare operating platform.

The PAT shortfall reflected lower EBITDA and a slightly higher tax rate. TruBridge acquisition-related costs also affected reported margins. Excluding this one-time acquisition impact, adjusted EBITDA margin was approximately 35%, flat quarter on quarter and in line with expectations.

TruBridge Acquisition Expands the Hospital Platform

Management described the TruBridge acquisition as transformational rather than simply revenue-accretive. TruBridge provides IKS access to more than 2,100 rural and community hospitals, where it has approximately 30% market share, and expands the company beyond large physician groups.

The combination of TruBridge’s electronic health record, described as a System of Record, with IKS workflow automation, described as a System of Action, is intended to create an integrated healthcare operating platform. IKS also expects to cross-sell its services into TruBridge’s customer base.

Management lowered TruBridge’s expected annual revenue to approximately US$300 million from US$340 million, reflecting more conservative revenue recognition, the exit from low-margin IT services and the rationalisation of certain business lines. Expected annual EBITDA remains approximately US$68 million, and management considers the transaction equally EPS-accretive.

Margin Recovery and AI-Led Operating Leverage

Management expects the combined EBITDA margin to moderate to 26-27% in the near term following TruBridge consolidation. It nevertheless expects the margin to return to a 30-36% range over the next few years through AI-led automation, offshore delivery, operational efficiencies, technology integration and cost synergies.

IKS has access to more than 5 million patient records through TruBridge, which management plans to de-identify for training proprietary small language models. Management expects these healthcare AI models to reduce dependence on commercial large language models, lower inference costs, and improve speed and margins.

Management reaffirmed its FY30 EBITDA target of Rs 30,000 million. It expects minimal equity dilution and leverage to return to pre-acquisition levels, supported by cash generation, operating leverage and productivity gains.

Customer Stickiness and Recent Wins

Revenue visibility is supported by customer retention, with more than 85% of revenue coming from repeat customers. The top 10 and top five customer relationships have an average tenure of more than five years. However, customer concentration has increased: the top 10 customers contributed 54% of 1Q FY27 revenue, while the top five contributed 42%.

Recent wins and expansions included:

• A clinical-data migration project for a California integrated health system.
• An Advocate Health expansion across revenue-cycle management.
• An end-to-end revenue-cycle management modernisation engagement with a musculoskeletal leader.
• An expanded mandate with StrideCare.

Estimates, Valuation and Execution Considerations

Motilal Oswal forecasts organic revenue, EBITDA and PAT compound annual growth rates of 17%, 19% and 20%, respectively, over FY26-28. The broker reduced FY27E and FY28E EPS by 3.1% and 6.8% to Rs 50.3 and Rs 60.7, primarily because of lower margin assumptions.

The broker values IKS at 34 times FY28E EPS to derive a target price of Rs 2,075. Key execution considerations are the integration of TruBridge, near-term dilution in combined margins, delivery of planned synergies, and conversion of AI-led productivity initiatives into sustained margin recovery.